AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30995373
Drug: UB-421 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UB-421 (25 mg/kg every 2 weeks)
Trial: 30996012
Drug: Selinexor 60
RxNorm normalized name: selinexor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 60 mg orally twice weekly on days 1 and 3 of each week, three of each 4-week cycle
Trial: 30997507
Drug: Low Energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Energy Density (LED) preload (33 kcal/100 g)
Trial: 30997507
Drug: High Energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Energy Density (HED) preload (97.9 kcal/100 g)
Trial: 30999933
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg or 4 mg with or without concomitant methotrexate (MTX)
Trial: 31003789
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (≥1.3 g of protein/kg)
Trial: 31003789
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake (<1.3 g of protein/kg)
Trial: 31003963
Drug: Emicizumab 6
RxNorm normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 6 mg/kg subcutaneously every 4 weeks for 24 weeks or more (with 4 loading doses of 3 mg/kg once weekly for the expansion cohort)
Trial: 31003963
Drug: Emicizumab 6
RxNorm normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 6 mg/kg subcutaneously every 4 weeks
Trial: 31004324
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg SC every 2 weeks + methotrexate
Trial: 31004598
Drug: Endoscopic eradication
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic eradication therapy (EET) with complete eradication of intestinal metaplasia (CE-IM)
Trial: 31005932
Drug: ICP monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICP monitoring and ICP-driven therapy
Trial: 31006811
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (25 g/d)
Trial: 31006980
Drug: HCV direct-acting
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV direct-acting antiviral (DAA) treatment
Trial: 31006980
Drug: Opioid substitutive
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid substitutive therapy (OST-PWID)
Trial: 31006980
Drug: Recent people
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recent people who inject drugs (recent PWID)
Trial: 31008307
Drug: Systems medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systems medicine approach to investigate complex risk-factor interactions
Trial: 31008354
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of medication compliance
Trial: 31009356
Drug: Intravenous tPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tPA therapy (IVT)
Trial: 31009701
Drug: 5-grass tablet
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-grass tablet (sublingual immunotherapy), daily dosage with a 3-day dose escalation to 300 index of reactivity (IR) for 30 days
Trial: 31010300
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living disability
Trial: 31010434
Drug: Ad5-GUCY2C-PADRE vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-GUCY2C-PADRE vaccine
Trial: 31011205
Drug: WINTHER therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WINTHER therapy
Trial: 31011207
Drug: CD19-BBz(86) CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-BBz(86) CAR T cell therapy, dose: 2 × 10^6 cells
Trial: 31011363
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 15 metabolites
Trial: 31011363
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 15 metabolites and motilin
Trial: 31012962
Drug: CC-486 300
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 300 mg daily on days 1 through 14 and romidepsin 8 mg/m²
Trial: 31012967
Drug: Imatinib with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib with standard-dose induction and consolidation therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) when possible.
Trial: 31012967
Drug: Rescue chemotherapy
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue chemotherapy and TKI change followed by second allo-HSCT for overt disease recurrence.
Trial: 31013390
Drug: CAM2038 weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAM2038 weekly (8, 16, 24 or 32 mg) or monthly (64, 96, 128 or 160 mg)
Trial: 31013390
Drug: CAM2038 weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAM2038 weekly or monthly
Trial: 31014072
Drug: Firibastat (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firibastat (250 mg BID for 2 weeks, then 500 mg BID if AOBP >140/90 mm Hg; hydrochlorothiazide 25 mg QD added after 1 month if AOBP ≥160/110 mm Hg)
Trial: 31015389
Drug: Intravenous triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous triiodothyronine (0.4 μg/kg bolus followed by 0.6 μg/kg continuous perfusion for 24 h)
Trial: 31016030
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) using a treat and extend (TAE) dosing regimen.
Trial: 31016233
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy in the NBRST study (NCT01479101) for ER-positive HER2-negative breast cancers.
Trial: 31018069
Drug: Tagraxofusp at
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tagraxofusp at a dose of 12 μg per kilogram
Trial: 31018069
Drug: Tagraxofusp at
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tagraxofusp at a dose of 7 μg per kilogram
Trial: 31018069
Drug: Tagraxofusp (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagraxofusp (both doses)
Trial: 31019106
Drug: Nusinersen (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nusinersen (12 mg, single-dose level)
Trial: 31023296
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy administered by injection every 4 weeks
Trial: 31024845
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose to reconstructed breast
Trial: 31024845
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no radiation dose specified)
Trial: 31024978
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with HEV239 vaccine
Trial: 31027916
Drug: Abivertinib (50-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abivertinib (50-350 mg twice daily or 300 mg twice daily)
Trial: 31028053
Drug: Family-administered FAM-CAM
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Family-administered FAM-CAM
Trial: 31028053
Drug: Family-administered Sour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-administered Sour Seven questionnaire
Trial: 31028495
Drug: EXAcerbations of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXAcerbations of COPD Tool (EXACT®) questionnaire, daily observations over a year.
Trial: 31028664
Drug: Ivosidenib 500
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivosidenib 500 mg QD
Trial: 31028664
Drug: Ivosidenib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (various doses from 100 mg BID to 1200 mg QD)
Trial: 31028664
Drug: Ivosidenib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (various doses)
Trial: 31030414
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg bid for 4 days, followed by apixaban 10 mg and clarithromycin 500 mg bid on day 8.
Trial: 31030414
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg alone on day 1 and day 8.
Trial: 31031265
Drug: High-dose opioids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose opioids (increased dose over the last 14 days)
Trial: 31031265
Drug: High-dose opioids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose opioids (no increase of dose over the last 14 days)
Trial: 31032113
Drug: Trypan blue
RxNorm normalized name: Trypan Blue
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trypan blue capsule staining during phacoemulsification
Trial: 31032113
Drug: Phacoemulsification without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phacoemulsification without trypan blue capsule staining (control)
Trial: 31033034
Drug: Dimethylfumarate monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylfumarate monotherapy
Trial: 31033194
Drug: Anticoagulants stopped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants stopped if d-dimer was negative
Trial: 31033194
Drug: Anticoagulants continued
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants continued if d-dimer was positive
Trial: 31033623
Drug: Isotope-labeled 3
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotope-labeled 3 mg aqueous zinc administered in the fasted state
Trial: 31034595
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with breast cancer receiving chemotherapy
Trial: 31035291
Drug: Mavacamten 10
RxNorm normalized name: mavacamten 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten 10 to 20 mg/d (cohort A)
Trial: 31035291
Drug: Mavacamten 2
RxNorm normalized name: mavacamten 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten 2 to 5 mg/d with β-blockers (cohort B)
Trial: 31036012
Drug: Non-biologic disease-modifying
RxNorm normalized name: cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biologic disease-modifying antirheumatic drugs (non-bDMARDs)
Trial: 31036012
Drug: Biologic disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic disease-modifying antirheumatic drugs (biologic DMARDs)
Trial: 31036770
Drug: Regorafenib 100
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 100 mg p.o. daily (continuous dosing)
Trial: 31036879
Drug: Anti-GITR-based combination
RxNorm normalized name: Anti-gitr agonistic monoclonal antibody incagn01876
DrugBank: Ragifilimab (DB18853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-GITR-based combination immunotherapy
Trial: 31038469
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine 10 mg on visit 1
Trial: 31038469
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 10 mg on visit 2
Trial: 31038469
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine 30 mg on visit 3
Trial: 31038469
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine 50 mg on visit 4
Trial: 31038781
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with LDL-C below the target of 70 mg/dL
Trial: 31038781
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who believe cholesterol treatment should be terminated when cholesterol normalizes
Trial: 31039789
Drug: Severity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severity of insulin resistance (measured by HOMA-IR)
Trial: 31039807
Drug: Intravenous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous abatacept (weight-tiered: <75 kg: 10 mg/kg; 75-100 kg: 750 mg; >100 kg: 1000 mg) administered at Weeks 0, 2, 4, and every 4 weeks thereafter for 16 weeks.
Trial: 31040256
Drug: EGFR-TKI (erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR-TKI (erlotinib 150 mg or gefitinib 250 mg per day) plus thoracic radiotherapy (54-60 Gy/27-30 F/5.5-6 w)
Trial: 31042669
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg subcutaneously twice-daily)
Trial: 31042825
Drug: bb2121 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bb2121 CAR T-cell therapy
Trial: 31043157
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration therapy (WBVT) - 20 Hz, 2 mm amplitude, 3 bouts of 3 minutes, 4 days per week for 4 weeks.
Trial: 31043157
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration therapy (WBVT)
Trial: 31043390
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D (1,000 IU/day)
Trial: 31043390
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (5,000 IU/day)
Trial: 31045222
Drug: Standard-dose intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose intradermal influenza vaccine
Trial: 31046714
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg q3w i.v. for 2 cycles)
Trial: 31046720
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity on Prescription (PAP) treatment including individual counseling, tailored PA recommendation, written prescription, and structured follow-up for 6 months
Trial: 31046720
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity on Prescription (PAP) treatment
Trial: 31046743
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every third week in combination with entinostat 5 mg orally once weekly.
Trial: 31046839
Drug: Intratumoral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral treatment with BO-112
Trial: 31046839
Drug: Intratumoral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral treatment with BO-112 plus systemic anti-CD137 and anti-PD-L1 mAbs
Trial: 31048330
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg Q2W
Trial: 31048330
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg Q2W, 240 mg Q2W, 360 mg once every 3 weeks
Trial: 31048330
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg, 240 mg, 360 mg
Trial: 31049885
Drug: Cannabidiol oral
RxNorm normalized name: cannabidiol Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol oral solution (5, 10, or 20 mg/kg single dose on day 1; 10 mg/kg, 20 mg/kg, or 40 mg/kg total daily dose for days 4-10)
Trial: 31049885
Drug: Cannabidiol oral
RxNorm normalized name: cannabidiol Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol oral solution (40 mg/kg/day) with clobazam
Trial: 31053102
Drug: Dietary information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary information and environmental factors (gestational age, mode of delivery, maternal/infant diet, exposure to antibiotics)
Trial: 31053156
Drug: HO volume
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HO volume measured by low-dose whole body CT
Trial: 31055613
Drug: anti-CD19 CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD19 CAR-T cell therapy
Trial: 31055613
Drug: replacement and
RxNorm normalized name: INVEST HORMONE THERAPY/REPLACEMENT ANDROGEN AND ANABOLIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: replacement and anticoagulant therapy
Trial: 31057004
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence (taking medications ≥90% of the time as prescribed)
Trial: 31057004
Drug: No medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medications prescribed during follow-up
Trial: 31057004
Drug: Taking ≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking ≥1 medications
Trial: 31057807
Drug: Carepartner and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carepartner and Constraint-Induced Therapy (CARE-CITE) with structured carepartner involvement during 30-h CIMT
Trial: 31057807
Drug: Constraint-Induced Movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Movement Therapy (CIMT) without structured carepartner involvement
Trial: 31058782
Drug: Additional antibiotic
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional antibiotic courses
Trial: 31060562
Drug: Omega-3 intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 intake < 1.7 g/day
Trial: 31060567
Drug: AS03-adjuvanted H5N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H5N1 vaccine (2-dose vaccination schedule)
Trial: 31060612
Drug: Carboplatin/paclitaxel (C + P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/paclitaxel (C + P) chemotherapy followed by HPV16-E7 synthetic long peptide (E7LP) vaccination
Trial: 31060612
Drug: Tri-therapy: C + P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-therapy: C + P chemotherapy, E7LP vaccination, and intravaginal CpG
Trial: 31060612
Drug: Nanoparticle-conjugated E7LP
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanoparticle-conjugated E7LP vaccine
Trial: 31061035
Drug: Frequent binge
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent binge drinking between the age of 18 and 25 years (defined as more than twice a month)
Trial: 31061070
Drug: Anti-PD-1 monotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 monotherapy
Trial: 31061070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of drugs targeting the IL17 signaling pathway with T-cell checkpoint inhibitors
Trial: 31061681
Drug: Urinary TIMP2∗IGFBP7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary TIMP2∗IGFBP7 concentration > 2.0 (ng/ml)
Trial: 31062633
Drug: Grape/pomegranate pomace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape/pomegranate pomace dietary supplement
Trial: 31063537
Drug: cART based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor
Trial: 31063862
Drug: Durvalumab, 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab, 1500 mg every 4 weeks, and Olaparib, 300 mg twice a day
Trial: 31064851
Drug: SY-1365, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-1365, a selective CDK7 inhibitor